Table 2.
Participant demographic and disease characteristics
| Total Sample (N = 630) |
HIV+ (n = 427) |
HIV- (n = 203) |
p | Group differences |
|
|---|---|---|---|---|---|
| Age (years) | 42.5 (13.9) | 42.3 (13.4) | 42.9 (15) | - | - |
| Education (years) | 13.6 (2.6) | 13.3 (2.5) | 14.2 (2.7) | <.0001 | H+ < HIV- |
| Ethnicity/Race | |||||
| African-American | 26% | 27.6% | 22.7% | - | - |
| Asian | 1.6% | 1.4% | 2% | - | - |
| Hispanic | 18.1% | 18.3% | 17.7% | - | - |
| White | 53.3% | 52% | 56.2% | - | - |
| Gender (% men) | 79.5% | 86.2% | 65.5% | < .0001 | H+ >HIV- |
| Major depression | 49.6% | 57.8% | 34.7% | < .0001 | H+ >HIV- |
| Generalized anxiety | 10.6% | 14% | 4.5% | .0002 | H+ >HIV- |
| Substance dependence | 49.3% | 54.5% | 39.9% | .0008 | H+ >HIV- |
| Hepatitis C Virus | - | 17.9% | 9.5% | .005 | H+ >HIV- |
| Estimated duration of Infection (months) |
- | 140.3 (100.2) | - | - | - |
| AIDS (%) | - | 50.9% | - | - | - |
| CD4 count (cells/mL) | - | 566.6 (284.9) | - | - | - |
| Nadir CD4 (cells/mL) | - | 231.1 (190.6) | - | - | - |
| cART status (% rx) | - | 84.1% | - | - | - |
| Plasma RNA (detectable) | - | 30.5% | - | - | - |
| On cART | - | 19.8% | - | - | - |
Note: AIDS = Acquired immune deficiency syndrome; CD4 = Cluster of differentiation 4; cART = combination antiretroviral therapy; Major depression, generalized anxiety, and substance dependence include lifetime diagnoses.